Semaglutide
Also known as · Ozempic · Wegovy
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
A long-acting GLP-1 receptor agonist for type-2 diabetes and weight management. Slows gastric emptying and suppresses appetite.
Binds GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, and delay gastric emptying.
Weekly subQ; titrate 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over months.
Refrigerated 2–8°C; in use, room temp up to ~6 weeks.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with superior weight loss and glycemic control versus semaglutide in head-to-head trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures yet in trials. Not yet approved.
Cagrilintide
A long-acting amylin analog studied for weight loss, often paired with semaglutide (CagriSema).